HT
AMLX icon

Headlands Technologies’s Amylyx Pharmaceuticals AMLX Stock Holding History

Headlands Technologies’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$275K Sell
19,814
-10,729
-35% -$151K 0.03% 518
2025
Q4 		$369K Buy
+30,543
New +$415K 0.03% 472

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Headlands Technologies's AMLX Position: Q1 2026 in Review

Headlands Technologies reduced its Amylyx Pharmaceuticals (AMLX) stake by 35% in Q1 2026, selling an estimated $151K and leaving 19,814 shares worth $275K. The position accounts for 0.03% of the portfolio, ranked #518.

Headlands Technologies first reported a position in AMLX in Q4 2025 and has held it in 2 quarters since. The position peaked at $369K in Q4 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Headlands Technologies held 19,814 shares of Amylyx Pharmaceuticals worth $275K as of Q1 2026.
  • Headlands Technologies sold 10,729 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $151K.
  • Amylyx Pharmaceuticals made up 0.03% of Headlands Technologies's portfolio in Q1 2026, its #518 holding.
  • Headlands Technologies first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Headlands Technologies's Amylyx Pharmaceuticals position peaked at $369K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.